Using multiplex IHC to identify myeloid derived suppressor cells and antigen presenting cells in NSCLC by King, Catherine
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2021
Using multiplex IHC to identify
myeloid derived suppressor cells




   
BOSTON UNIVERSITY 
 











USING MULTIPLEX IHC TO IDENTIFY MYELOID DERIVED SUPPRESSOR 





















Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2021 






































© 2021 by 
 CATHERINE KING 










First Reader   
 Elizabeth R. Duffy, M.A. 






Second Reader   
 Christopher D. Andry, M.Phil., Ph.D. 
 Professor, Chief and Chair of Pathology & Laboratory Medicine 
 Professor of Family Medicine 
iv 
ACKNOWLEDGMENTS 
This thesis is based on work completed at Bristol Myers Squibb. I am grateful for my 
colleagues who supported me with the completion of this thesis, including Anne Lewin 
and Ben Chen for helpful advice and overseeing the project, Jimena Trillo for pathology 
review and analysis guidance, and Andrew Fisher for halo advice. 
 
 v 
USING MULTIPLEX IHC TO IDENTIFY MYELOID DERIVED SUPPRESSOR 
CELLS AND ANTIGEN PRESENTING CELLS IN NSCLC 
CATHERINE KING 
ABSTRACT 
 Lung cancer is considered one of the deadliest cancers worldwide, with a five-
year survival rate of under 20% [8]. There are three different categories of NSCLC 
tumors: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The most 
common of the tumor types is adenocarcinoma [13]. Different cell types that make up the 
tumor microenvironment contribute to the treatment response and prognosis of the 
disease. Myeloid-derived suppressor cells (MDSCs) have been shown to be increased in 
cancer patients compared to healthy individuals. These cells are immunosuppressive and 
there is evidence that MDSCs play a role in drug resistance, tumor metastases, and 
suppression of immune cells in cancer [3]. Antigen presenting cells (APCs) are immune 
cells that present antigens to B cells, macrophages, and dendritic cells.  Tumors can 
become resistant to immunotherapy by evading T cells through modulating antigen 
presentation by surface MHC (major histocompatibility complex) [7]. APCs use MHC to 
present antigens and interact with T cells. This interaction influences T cell activation and 
differentiation [4]. Characterizing differences in MDSCs and APCs between normal lung 
samples and NSCLC samples may be helpful in identifying mechanisms of tumor 
progression and treatment resistance. Multiplex IHC (immunohistochemistry) is a useful 
technique for the identification of MDSCs and APCs and it allows for the visualization of 
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 Lung cancer is among the most common cancer types worldwide and is 
considered one of the deadliest cancers, responsible for over 1 million deaths in the 
United States in 2018 [8]. The five-year survival rate for lung cancer is 18.6%, which is 
lower than other cancers including breast, prostate, and colorectal. One contributing 
factor to the low five-year survival rate is that only 16% of lung cancers are diagnosed in 
the early stage of the disease [8]. The leading causes of lung cancer include smoking, 
followed by radon exposure, then occupational exposures to carcinogens like asbestos 
[8]. 
 Non-small cell (NSCLC) and small cell (SCLC) are the two main types of lung 
cancer. SCLC is less common than NSCLC but it is more aggressive. NSCLC makes up 
85% of lung cancers. There are three different categories of NSCLC tumors: 
adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The most common 
of the tumor types is adenocarcinoma. This type originates in the glandular epithelium 
and grows slower relative to the other subtypes. Squamous cell carcinoma begins in the 
squamous cells of the inner airways and accounts for about one fourth of lung cancers. 
About 10% of lung cancers are large cell carcinoma, which grow and spread faster than 
the other subtypes [13]. Treatment depends on the type of cancer. Surgery, radiation, 
chemotherapy, immunotherapy, targeted therapy, or a combination of treatments is used 
for NSCLC. Chemotherapy and radiation are usually used for small cell lung cancer. [5]. 
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 Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells derived 
from bone marrow. These cells are increased in cancer patients compared to healthy 
individuals. There is evidence that MDSCs play a role in drug resistance, tumor 
metastases, and suppression of immune cells in cancer [9]. There are two main groups of 
MDSCs: polymorphonuclear (PMN-MDSC) and monocytic (M-MDSC) [4]. M-MDSCs 
are defined by the phenotype CD11b+ CD14+ CD15- HLADR-/low [17].  PMN-MDSCs are 
defined by the phenotype CD11b+ CD15+ CD14- HLADR-/low [15]. These MDSCs are in a 
paused development state from myeloid to monocytic (M-MDSC) or to neutrophil 
(PMN-MDSC) differentiation [15]. HLA-DR is a MHCII receptor expressed on the 
membrane of APCs (antigen presenting cells) [12]. MDSCs function through a variety of 
mechanisms to inhibit T cell activation and mediate macrophage and NK cell function in 
the tumor microenvironment [11].  This suppression of immune cells influences 
antitumor immunity which affects response to immunotherapies [11]. In patients with 
NSCLC, MDSCs were associated with metastasis and poor response to treatment [9]. 
 Antigen presenting cells are immune cells like B cells, macrophages, and 
dendritic cells that present antigens to T cells [7].  Tumors can become resistant to 
immunotherapy by evading T cells. One mechanism for this resistance is related to 
antigen presentation by MHC (major histocompatibility complex) [7]. MHCI is involved 
with activation of CD8+ T cells and MHCII is involved with activation of CD4+ T cells 
[16]. APCs use MHC to present antigens and interact with T cells. This interaction 
influences T cell activation and differentiation [4]. APCs that do not express MHCII do 
not activate CD4+ T cells and can be immunosuppressive in the tumor microenvironment 
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[16]. MHCII has been studied in NSCLC and is a useful indicator for prognosis and for 
selecting treatment, such as immunotherapy [16].  
 Characterizing differences in MDSCs and APCs between normal lung samples 
and NSCLC samples may be helpful in identifying mechanisms of tumor progression and 
treatment resistance [16,9]. One technique that could be used for this is multiplex IHC 
(immunohistochemistry).  Multiplex IHC is a useful technique in cancer research. It 
allows for the identification of cell phenotypes with multiple markers within the context 
of tumor microenvironment. IHC is typically completed with one marker per section and 
is visualized using DAB (3,3’-diaminobenzidine) [2]. Tissue is stained using a primary 
antibody against the marker of interest, then a secondary antibody with horseradish 
peroxidase catalyzes the oxidation of DAB [2]. The DAB precipitates and the brown 
chromogen can be seen with light microscopy [2]. Multiplex IHC can be chromogenic or 
fluorescent. One technology for fluorescent multiplex is the use of DNA barcodes to pair 
antibodies to fluorophores [10]. Using four markers and four paired fluorophores that are 
spectrally far apart allows for all markers to be visualized on the same sample without 
spectral un-mixing. The purpose of this project is to validate multiplex panels for use and 
to identify MDSC and APC populations in normal and cancer samples using multiplex 
IHC.  DAB monoplex staining was compared to fluorescent monoplex staining for each 
marker in both panels to validate that the fluorescent staining is reliable. Single channels 
from multiplex staining were also compared to the fluorescent monoplex staining to 
validate that the monoplex and multiplex staining were comparable. Next, five normal 
lung samples and five NSCLC samples were stained with two separate multiplex IF 
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panels for the assessment of MDSCs and APCs in each sample type. The MDSC panel 
includes CD11b, CD14, CD15, and HLA-DR. CD11b is a marker used to identify 
myeloid cells. CD11b cells that are also positive for CD14 and HLA-DR are the 
monocyte population. The PMNs were identified by CD11b, CD15, and HLA-DR. HLA-
DR is a marker for antigen presenting cells. MDSCs express low HLA-DR or are 
negative for HLA-DR [15].  The APC panel includes CD11c, CD20, CD68/CD163, and 
MHCII. CD11c is a marker for dendritic cells. CD20 is B cell marker. Macrophages are 
detected in the panel using a CD68 and CD163 cocktail. MHCII is an antigen presenting 







Five NSCLC FFPE (formalin-fixed, paraffin-embedded), five normal lung FFPE, 
and one tonsil FFPE sample were acquired from commercial vendors. Samples were 
sectioned at 5m for all staining performed. Hematoxylin and eosin staining of tissues 
was completed and slides were reviewed by pathologist for confirmation of tissue type 
and diagnosis. 
Immunohistochemistry (IHC) 
 Eight sections of tonsil were stained with a single marker from the table below. 
CD68 and CD163 were stained as a cocktail on the same slide. All antibodies were 
diluted in Dako Protein block (catalogue number: X0909). Slides were baked, dewaxed, 
and DAB IHC staining was completed on the Leica Bond Rx using the Bond Polymer 
Refine Detection kit. Slides were then dehydrated by placing in water, then in ethanol 
(70%, 95%, 100%) in order of increasing percentages, then in xylene and finally 
mounted. All DAB IHC stained slides were scanned on the Aperio AT2 (Leica) scanner.   
Antibody Clone Catalogue Number (Supplier) 
CD11c EP1347Y Ab216655 (Abcam) 
CD20 L26 Ab9475 (Abcam) 
CD68/ CD163 KP1/ EPR19518 Ab783 (Abcam)/ Ab20034 (Abcam) 
MHCII CR3/43 M0775 (Dako) 
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CD11b SP331 Ab238794 (Abcam) 
CD14 SP192 Ab230903 (Abcam) 
CD15 Leu-M1 Ab212391 (Abcam) 




 Fluorescent IHC was completed on five NSCLC FFPE, five normal lung FFPE, 
and one tonsil sample. Slides were baked, dewaxed, and fluorescent IHC staining was 
completed on the Leica Bond Rx using the Ultivue APC and MDSC kit reagents. See 
table below for markers in each panel. Monoplex staining for each marker was completed 
on eight tonsil sections for comparison to DAB monoplex staining. Multiplex staining for 
each kit was completed on the tonsil, NSCLC and normal lung samples. After staining 
slides were mounted and scanned on the Akoya Vectra Polaris.  
Ultivue Kit Catalogue Number Antibody Clone 
APC ULT20111 CD11c EP1347Y 
CD20 L26 
CD68/ CD163 KP1/ EPR19518 
MHCII CR3/43 





HLA-DR TAL 1B5 
 
Halo Analysis 
  Analysis for all staining was performed using Indica Halo analysis software.  
For DAB staining and fluorescent monoplex staining, five regions of interest (ROIs) were 
selected for analysis and comparison. The same ROIs were selected for each marker on 
both DAB and fluorescent slides. For fluorescent multiplex staining, tissue was annotated 
and cell counts were obtained for phenotypes listed in table. A pathologist reviewed 
tissue annotations, cell segmentation, marker and phenotype detection of algorithms.  
Ultivue Panel Phenotype Markers 
APC Dendritic Cells CD11c+ 
APC  Dendritic Cells CD11c+ 
MHCII+ 
B Cells CD20+ 
APC B Cells CD20+ 
MHCII+ 
Macrophages CD68/CD163+ 
APC Macrophages CD68/CD163+ 
MHCII+ 
Total APCs MHCII+ 
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Statistical analysis was completed using Microsoft excel and Prism9 graph 
pad. Statistics include finding mean percentage of positive cells per marker for each 
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group of five normal and five NSCLC samples, standard deviations, and range of 






 Tissue selection was based on H&E staining and pathology review. One tonsil, 
five NSCLC, and five normal lung tissues were selected. Out of the five NSCLC 












Figure 1: Hematoxylin and Eosin Staining on Tonsil, Normal Lung, and NSCLC 
samples. H&E staining for selected samples. A. H&E for tonsil sample selected for assay 
validation. B. H&E of normal lung samples selected for MDSC and APC panels. C. H&E 
of NSCLC samples selected for MDSC and APC panels. S001892 and S001894 are 
adenocarcinoma. S001898, S001899, and S001900 are squamous cell carcinoma.  
 
 
 Tonsil was used for assay validation. DAB and fluorescent monoplex staining 
were completed on serial sections of tonsil for each marker in the two Ultivue panels 
(Figure 2 and Figure 3). Results showed equivalent staining for pattern and percentage 













Figure 2: DAB and Fluorescent Monoplex Staining on Serial Tonsil Sections for 
Markers in the Ultivue MDSC Panel. Halo masks are included under each image which 
show cells detected as positive for each marker. A. CD11b DAB and fluorescent (green) 
IHC. B. CD14 DAB and fluorescent (yellow) IHC. C. CD15 DAB and fluorescent (red) 














Figure 3: DAB and Fluorescent Monoplex Staining on Serial Tonsil Sections for 
Markers in the Ultivue APC Panel. Halo masks are included under each image which 
show cells detected as positive for each marker. A. CD20 DAB and fluorescent (green) 
IHC. B. CD68/CD163 DAB and fluorescent (yellow) IHC. C. CD11c DAB and 








Figure 4: Percent Positive Cells in DAB and Fluorescent Monoplex Staining on 
Serial Tonsil Sections for Markers in Ultivue Panel. A. Percent positive cells from 
Halo analysis (5 ROIs per slide) for each marker in MDSC panel B. Percent positive cells 
from Halo analysis (5 ROIs per slide) for each marker in APC panel 
 


































































 Each kit was run as 4-plex panel on tonsil (Figure 5). Results showed comparable 


















































Figure 5: Multiplex Panels on Tonsil Sample. A. Multiplex MDSC panel B. Single 
channel staining from multiplex MDSC panel. C. Percent positive cells from Halo 
analysis (5 ROIs per slide) for each marker in MDSC panel including DAB and 
fluorescent monoplexes compared to single channel multiplex staining. D. Multiplex 
APC panel. E. Single channel staining from multiplex APC panel. F. Percent positive 
cells from Halo analysis (5 ROIs per slide) for each marker in APC panel including DAB 
and fluorescent monoplexes compared to single channel multiplex staining. 
 



































The MDSC panel and APC panel were run on five normal lung and five NSCLC 
samples (Figure 6). Halo was used for analysis and phenotyping. Intensity thresholds for 
each marker were set and phenotypes were established according to table in methods 
section. MDSC were detected in both normal lung and NSCLC samples (Figure 7). The 
MDSC results showed that normal lung had a higher percentage of myeloid cells, MDSC 
cells (both M- MDSC and PMN-MDSC), and HLA-DR compared to NSCLC.  The APC 
results showed that there were a higher percentage of cells that express MHCII (total) and 
MHCII in macrophages and dendritic cells in normal lung samples compared to NSCLC 














Figure 6: Overview of Multiplex Panel Staining in Normal Lung and NSCLC. A. 
Multiplex MDSC staining in normal lung. B. Multiplex MDSC staining in NSCLC. C. 







Figure 7: MDSC Normal Lung and NSCLC. A. Multiplex MDSC staining in normal 









Figure 8: APC Normal Lung and NSCLC. A. Multiplex APC staining in normal lung. 













Figure 9: Percent Positive Cells per Phenotype in MDSC Panel. A. Percent of 
myeloid cells in normal lung compared to NSCLC. B. Percent of PMN cells and PMN-
MDSC in normal lung compared to NSCLC. C. Percent of monocytes and M-MDSC in 
normal lung compared to NSCLC. D. Percent of HLA-DR positive cells in normal lung 



























































Figure 10: Percent Positive Cells per Phenotype in APC Panel. A. Percent of dendritic 
cells in normal lung compared to NSCLC. B. Percent of B cells in normal lung compared 
to NSCLC. C. Percent of macrophages in normal lung compared to NSCLC. D. Percent 
of MHCII positive cells in normal lung compared to NSCLC. 
 
































Figure 11: CD20 Positive Cells in NSCLC. A. Image of CD20 positive staining in 





















 Assay validation included comparing DAB staining to fluorescent staining, which 
is important for confirming the fluorescent staining is performing as expected. The 
multiplex technology uses DNA barcoded antibodies to stain the tissue [10]. Then the 
complementary fluorescent DNA probes bind to the target barcoded antibody [10]. Assay 
validation results showed DAB monoplex staining for each marker is equivalent to the 
fluorescent monoplex staining in serial sections of tonsil. Five regions of interest were 
selected from each slide for comparison. The same ROIs were chosen for each maker for 
DAB and fluorescent monoplex staining. The percentage of positive cells was within 5% 
for each marker.  Results also showed equivalent staining pattern between the monoplex 
fluorescent slides and each marker/channel in the multiplex stained tonsil sample for both 
Ultivue panels. The single channel multiplex positive cells were within 20% of the 
monoplex positive cell staining. The differences between the multiplex and monoplex 
staining were acceptable considering tissue heterogeneity. One multiplex slide was run 
for comparison to all monoplex slides and therefore was not a serial section for all 
markers within each panel. These results support the validation of each Ultivue panel for 
use.   
The MDSC results showed higher percentage of M-MDSCs and PMN-MDSCs in 
normal lung compared to NSCLC samples. These cells have the phenotype for MDSCs 
but more studies are needed to show that the function of these cells is suppressive. Patient 
outcome is another factor that should be explored as an explanation. MDSCs are 
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associated with poor outcome. It is possible the samples that were included for testing did 
not have poor outcome, and therefore would not be expected to have a relatively high 
amount of functioning MDSCs. More samples should be included in future studies to 
confirm the findings from this study.  
The APC results showed higher dendritic cells and macrophages, both with and 
without MHCII, and higher percent of cells expressing MHCII. B cells, both with and 
without MHCII, were higher in the NSCLC samples compared to normal lung. One 
NSLC sample had a higher percentage of CD20 positive cells than all other samples 
(S001892) (Figure 11). This sample had TLS (tertiary lymphoid structures) across the 
sample which increased the average percent positive B cell counts in NSCLC. TLS are 
associated with better patient outcomes, which could help explain the MDSC results. 
Patient data is needed to confirm outcome.  
This study showed comparable staining between DAB and fluorescent samples, in 
both the monoplex and single chanel multiplex images. This result validated the 
multiplex panels for use. MDSCs were higher in normal samples compared to NSCLC 
samples. All APCs expect B cells were found to be higher in the normal samples 
compared to the NSCLC samples. TLS were present in the NSCLC samples, which 
contributed to the higher B cells compared to normal samples. More studies are needed to 
confirm results from this study. More samples should be included for staining with these 
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